TY - JOUR
T1 - Secreted IGFBP5 mediates mTORC1-dependent feedback inhibition of IGF-1 signalling
AU - Ding, Ming
AU - Bruick, Richard K.
AU - Yu, Yonghao
N1 - Funding Information:
We thank J. Goldstein, J. Blenis, M. White, M. Cobb and B. Tu for critically reviewing the manuscript. We thank J. Minna and D. Kwiatkowski for providing critical reagents, and N. Williams, H. Wang, H. Chen and L. Wu for input and technical guidance. This work was supported in part by grants from the UT Southwestern Endowed Scholar Program (to Y.Y. and R.K.B.), the Cancer Prevention and Research Institute of Texas (CPRIT R1103 to Y.Y. and CPRIT RP130513 to R.K.B.), the Welch Foundation (I-1800 to Y.Y. and I-1568 to R.K.B.), National Institutes of Health (NIH; GM114160 to Y.Y.), American Cancer Society (Research Scholar Grant, RSG-15-062-01-TBE, and Institutional Research Grant, IRG-02-196-07, to Y.Y.), and a Career Award in the Biomedical Sciences from the Burroughs Wellcome Fund (to R.K.B.). Y.Y. is a Virginia Murchison Linthicum Scholar in Medical Research and a CPRIT Scholar in Cancer Research. R.K.B. is the Michael L. Rosenberg Scholar in Medical Research.
Funding Information:
We thank J. Goldstein, J. Blenis, M. White, M. Cobb and B. Tu for critically reviewing the manuscript. We thank J. Minna and D. Kwiatkowski for providing critical reagents, and N. Williams, H. Wang, H. Chen and L. Wu for input and technical guidance. This work was supported in part by grants from the UT Southwestern Endowed Scholar Program (to Y.Y. and R.K.B.), the Cancer Prevention and Research Institute of Texas (CPRIT R1103 to Y.Y. and CPRIT RP130513 to R.K.B.), the Welch Foundation (I-1800 to Y.Y. and I-1568 to R.K.B.), National Institutes of Health (NIH; GM114160 to Y.Y.), American Cancer Society (Research Scholar Grant, RSG- 15-062-01-TBE, and Institutional Research Grant, IRG-02-196-07, to Y.Y.), and a Career Award in the Biomedical Sciences from the Burroughs Wellcome Fund (to R.K.B.). Y.Y. is a Virginia Murchison Linthicum Scholar in Medical Research and a CPRIT Scholar in Cancer Research. R.K.B. is the Michael L. Rosenberg Scholar in Medical Research.
Publisher Copyright:
© 2016 Macmillan Publishers Limited.
PY - 2016/2/25
Y1 - 2016/2/25
N2 - The PI(3)K-Akt-mTORC1 pathway is a highly dynamic network that is balanced and stabilized by a number of feedback inhibition loops1,2. Specifically, activation of mTORC1 has been shown to lead to the inhibition of its upstream growth factor signalling. Activation of the growth factor receptors is triggered by the binding of their cognate ligands in the extracellular space. However, whether secreted proteins contribute to the mTORC1-dependent feedback loops remains unclear. We found that cells with hyperactive mTORC1 secrete a protein that potently inhibits the function of IGF-1. Using a large-scale, unbiased quantitative proteomic platform, we comprehensively characterized the rapamycin-sensitive secretome in TSC2-/-mouse embryonic fibroblasts, and identified IGFBP5 as a secreted, mTORC1 downstream effector protein. IGFBP5 is a direct transcriptional target of HIF1, which itself is a known mTORC1 target3. IGFBP5 is a potent inhibitor of both the signalling and functional outputs of IGF-1. Once secreted, IGFBP5 cooperates with intracellular branches of the feedback mechanisms to block the activation of IGF-1 signalling. Finally, IGFBP5 is a potential tumour suppressor, and the proliferation of IGFBP5-mutated cancer cells is selectively blocked by IGF-1R inhibitors.
AB - The PI(3)K-Akt-mTORC1 pathway is a highly dynamic network that is balanced and stabilized by a number of feedback inhibition loops1,2. Specifically, activation of mTORC1 has been shown to lead to the inhibition of its upstream growth factor signalling. Activation of the growth factor receptors is triggered by the binding of their cognate ligands in the extracellular space. However, whether secreted proteins contribute to the mTORC1-dependent feedback loops remains unclear. We found that cells with hyperactive mTORC1 secrete a protein that potently inhibits the function of IGF-1. Using a large-scale, unbiased quantitative proteomic platform, we comprehensively characterized the rapamycin-sensitive secretome in TSC2-/-mouse embryonic fibroblasts, and identified IGFBP5 as a secreted, mTORC1 downstream effector protein. IGFBP5 is a direct transcriptional target of HIF1, which itself is a known mTORC1 target3. IGFBP5 is a potent inhibitor of both the signalling and functional outputs of IGF-1. Once secreted, IGFBP5 cooperates with intracellular branches of the feedback mechanisms to block the activation of IGF-1 signalling. Finally, IGFBP5 is a potential tumour suppressor, and the proliferation of IGFBP5-mutated cancer cells is selectively blocked by IGF-1R inhibitors.
UR - http://www.scopus.com/inward/record.url?scp=84959232463&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959232463&partnerID=8YFLogxK
U2 - 10.1038/ncb3311
DO - 10.1038/ncb3311
M3 - Article
C2 - 26854565
AN - SCOPUS:84959232463
SN - 1465-7392
VL - 18
SP - 319
EP - 327
JO - Nature cell biology
JF - Nature cell biology
IS - 3
ER -